Readystate Asset Management LP Increases Stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)

Readystate Asset Management LP increased its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 129.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 481,241 shares of the company's stock after purchasing an additional 271,899 shares during the quarter. Readystate Asset Management LP owned 0.84% of Structure Therapeutics worth $8,330,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Virtus ETF Advisers LLC grew its holdings in shares of Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after purchasing an additional 455 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Structure Therapeutics by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 45,705 shares of the company's stock worth $1,240,000 after purchasing an additional 480 shares during the last quarter. LPL Financial LLC grew its holdings in shares of Structure Therapeutics by 6.0% in the fourth quarter. LPL Financial LLC now owns 11,485 shares of the company's stock worth $311,000 after purchasing an additional 646 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in Structure Therapeutics by 12.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock worth $201,000 after acquiring an additional 843 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new stake in Structure Therapeutics in the fourth quarter worth about $34,000. Institutional investors own 91.78% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on GPCR shares. HC Wainwright lowered their price objective on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, June 23rd. JMP Securities reaffirmed a "market outperform" rating and issued a $89.00 price objective on shares of Structure Therapeutics in a research note on Monday, June 23rd. Finally, Citigroup started coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has a consensus rating of "Buy" and a consensus price target of $76.17.

Structure Therapeutics Trading Down 1.8%

Shares of NASDAQ:GPCR traded down $0.33 during trading on Friday, reaching $17.94. The stock had a trading volume of 558,523 shares, compared to its average volume of 865,661. Structure Therapeutics Inc. Sponsored ADR has a one year low of $13.22 and a one year high of $45.37. The company has a market capitalization of $1.03 billion, a P/E ratio of -20.62 and a beta of -1.87. The firm's 50-day simple moving average is $21.25 and its 200 day simple moving average is $22.56.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). Equities research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.